徳島大学 教育・研究者情報データベース(EDB)

1. (英) Abe Masahiro

   役割	任意
   貢献度	任意
   学籍番号	推奨

2. 滝口 祥令

   役割	任意
   貢献度	任意
   学籍番号	推奨

3. (英) Ichimaru Satoshi

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. (英) Kaji Shinichiro

   役割	任意
   貢献度	任意
   学籍番号	推奨

5. 土屋 浩一郎([徳島大学.大学院医歯薬学研究部.薬学域.薬科学部門.生命薬学系.医薬品機能生化学]/[徳島大学.医学部.医学科.病態情報医学講座])

   役割	任意
   貢献度	任意
   学籍番号	推奨

6. (英) Wada Koichiro

   役割	任意
   貢献度	任意
   学籍番号	推奨

(英) Different effect of acute treatment with rosiglitazone on rat myocardial ischemia/reperfusion injury by administration method.

(英) The present study was undertaken to examine the effect of rosiglitazone, a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, using different administration methods, on rat myocardial infarct size induced by 30 min of ischemia followed by 4 h of reperfusion. The infarct size was significantly reduced by the continuous infusion of rosiglitazone (0.5 mg/kg/h) from 30 min before occlusion for 2 h. On the other hand, limitation of the infarct size was shown by a bolus injection of 0.75 mg/kg at 5 min before reperfusion, but not by a bolus injection of 1 mg at 30 min before occlusion. The protective effect of rosiglitazone by the bolus injection before occlusion was obtained when an antioxidant, N-acetylcysteine, was concomitantly administered. The cardioprotection by rosiglitazone was associated with the inhibition of increased myeloperoxidase activity, tumor necrosis factor-alpha content and phosphorylation of inhibitor kappaB in the myocardium. The present study demonstrated that the protective effect of rosiglitazone on myocardial ischemia/reperfusion injury occurred most likely by inhibition of the nuclear factor-kappaB pathway through PPAR-gamma activation. However, acute treatment with rosiglitazone is harmful if its concentration is high during ischemia.

1. (英) Acetylcysteine
2. (英) Animals
3. (英) Antioxidants
4. (英) Computer Simulation
5. (英) Disease Models, Animal
6. (英) Dose-Response Relationship, Drug
7. (英) Drug Administration Schedule
8. (英) I-kappa B Proteins
9. (英) Infusions, Intravenous
10. (英) Injections, Intravenous
11. (英) Male
12. (英) Models, Biological
13. (英) Myocardial Infarction
14. (英) Myocardial Reperfusion Injury
15. 心筋(myocardium)
16. (英) NF-kappa B
17. (英) PPAR gamma
18. (英) Peroxidase
19. リン酸化(phosphorylation)
20. (英) Protective Agents
21. (英) Rats
22. (英) Rats, Wistar
23. (英) Thiazolidinediones
24. (英) Tumor Necrosis Factor-alpha

1. (英) Article.Affiliation: Department of Clinical Pharmacology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan. abe19791016@yahoo.co.jp <abe19791016@yahoo.co.jp>

2. (英) Article.PublicationTypeList.PublicationType: Comparative Study

3. (英) Article.PublicationTypeList.PublicationType: Journal Article